CAMP4 Therapeutics Corporation Investment Income, Interest
CAMP4 Therapeutics Corporation (CAMP) reported Investment Income, Interest of $807.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- CAMP4 Therapeutics Corporation investment income, interest for the quarter ending 2026-06-30 was $807.00K, a 78.15% increase year-over-year.
- CAMP4 Therapeutics Corporation investment income, interest for the quarter ending 2026-03-31 was $910.00K, a 54.76% increase year-over-year.
- CAMP4 Therapeutics Corporation investment income, interest for the quarter ending 2025-12-31 was $710.00K, a 16.39% increase year-over-year.
- CAMP4 Therapeutics Corporation investment income, interest for the quarter ending 2025-09-30 was $423.00K, a 350.00% increase year-over-year.
- CAMP4 Therapeutics Corporation investment income, interest for fiscal 2025 was $2.17M, a 63.46% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation investment income, interest for fiscal 2024 was $1.33M, a 52.64% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation investment income, interest for fiscal 2023 was $2.81M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $807.00K 10-Q · filed 2026-08-13 | $1.72M 10-Q · filed 2026-08-13 | $2.43M derived: sum of 3 quarters · filed 2026-08-13 | $2.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $910.00K 10-Q · filed 2026-05-07 | $1.62M derived: sum of 2 quarters · filed 2026-05-07 | $2.04M derived: sum of 3 quarters · filed 2026-05-07 | $2.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $710.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.13M derived: sum of 2 quarters · filed 2026-03-05 | $1.59M derived: sum of 3 quarters · filed 2026-08-13 | $2.17M 10-K · filed 2026-03-05 |
| 2025-09-30 | $423.00K 10-Q · filed 2025-11-06 | $876.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.46M 10-Q · filed 2025-11-06 | $2.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $453.00K 10-Q · filed 2026-08-13 | $1.04M 10-Q · filed 2026-08-13 | $1.65M derived: sum of 3 quarters · filed 2026-08-13 | $1.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $588.00K 10-Q · filed 2026-05-07 | $1.20M derived: sum of 2 quarters · filed 2026-05-07 | $1.29M derived: sum of 3 quarters · filed 2026-05-07 | $1.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $610.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $704.00K derived: sum of 2 quarters · filed 2026-03-05 | $935.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.33M 10-K · filed 2026-03-05 |
| 2024-09-30 | $94.00K 10-Q · filed 2025-11-06 | $325.00K derived: sum of 2 quarters · filed 2025-11-06 | $720.00K 10-Q · filed 2025-11-06 | $1.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $231.00K 10-Q · filed 2025-08-14 | $626.00K 10-Q · filed 2025-08-14 | $1.20M derived: sum of 3 quarters · filed 2025-08-14 | $1.88M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $395.00K 10-Q · filed 2025-05-13 | $964.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.65M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.26M derived: sum of 2 quarters · filed 2025-03-27 | $2.81M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $689.00K 10-Q · filed 2024-11-21 | $2.24M 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |